SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 1-Year High After Analyst Upgrade

SOPHiA GENETICS SA (NASDAQ:SOPH) shares reached a new 52-week high on Wednesday after BTIG Research raised their price target on the stock from $8.00 to $9.00. BTIG Research currently has a buy rating on the stock. SOPHiA GENETICS traded as high as $7.20 and last traded at $7.0120, with a volume of 2764 shares. The stock had previously closed at $6.84.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Insider Activity

In related news, CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer directly owned 670,651 shares in the company, valued at approximately $3,500,798.22. This represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the sale, the insider owned 614,887 shares in the company, valued at $3,178,965.79. This represents a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 221,092 shares of company stock worth $1,250,070. Corporate insiders own 4.88% of the company’s stock.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Raised 2026 outlook: SOPHiA GENETICS increased its full-year revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the approximately $93.4 million analyst consensus. Management also expects to reach adjusted EBITDA breakeven by year-end, an important milestone for the currently loss-making company. SOPHiA GENETICS 2026 outlook
• Positive Sentiment: Revenue beat and improving EBITDA: Second-quarter revenue rose 27% year over year to $23.3 million, ahead of the $21.7 million consensus estimate. The adjusted EBITDA loss narrowed 27% to $8.8 million, indicating progress toward profitability. SOPHiA GENETICS Q2 2026 results
• Positive Sentiment: AstraZeneca partnership: The company entered a multiyear global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision-oncology therapies. The agreement could expand SOPHiA’s role in pharmaceutical development and commercial testing, although financial terms were not disclosed. SOPHiA GENETICS AstraZeneca collaboration
• Negative Sentiment: Bottom-line miss: SOPHiA GENETICS reported a second-quarter loss of $0.26 per share, worse than the $0.21 consensus estimate. Net loss remained elevated at $22.4 million, while reported and adjusted gross margins declined from the prior-year period. SOPHiA GENETICS earnings report

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares during the period. Akre Capital Management LLC lifted its holdings in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 1st quarter worth approximately $2,157,000. Royce & Associates LP purchased a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the 1st quarter valued at approximately $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

The stock has a market cap of $588.24 million, a price-to-earnings ratio of -13.48 and a beta of 0.96. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company’s fifty day moving average is $5.52 and its two-hundred day moving average is $5.11.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. As a group, research analysts predict that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.